Skip to main content

Advertisement

Table 3 Effect sizes for Efficacy Outcome Measures Across Treatment Phases

From: A pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention-deficit/hyperactivity disorder

Measures ATX +MPH (n= 9) ATX + PBO (excl. ER) (n= 8) ALL ATX + PBO (n= 12)
ADHD RS-IV-Parent:Inv T score    
   Overall effect 1.3*** 1.2** 1.3***
   Incremental effect 0.05 0.18 0.03
WREMB-AM    
   Overall effect 0.60 0.82 0.79
   Incremental effect 0.43 0.07 0.11
WREMB-PM    
   Overall effect 0.56 0.70 0.94*
   Incremental effect 0.33 0.01 0.02
CGI-Severity    
   Overall effect 1.3* 1.3** 1.4**
   Incremental effect .34 .38 0.25
Conner Parent Rating Scale    
   Overall effect 1.2* 0.80** 0.98***
   Incremental 0.18 0.09 0.07
  1. Key: ER, Early responders; ADHD-RS-IV-Parent:Inv, ADHD Rating Scale Parent Report Investigator Rated; WREMB, Weekly Ratings Evening and Morning Behaviors. Note: Overall effect size was from baseline to study end-point (10 weeks ATX treatment); Incremental effect size from double-blind randomization to study end-point (6 weeks augmentation treatment).
  2. *P ≤ .05, within group; **P ≤ .01, within group; *** P ≤ .001, within group from baseline